Search for content, post, videos

Affibody in agreement with 3P Biopharmaceuticals

Affibody agreement 3P

The agreement with 3P Biopharmaceuticals (3P) covers process development and GMP manufacturing of Affibody’s ABY-035 drug.

“Ensuring large scale high quality production of our ABY-035 drug is a natural next step in our evolution as a company with the ambition to have development, manufacturing, and commercialization expertise”, said David Bejker, CEO of Affibody. “The work we have initiated together with 3P is important for us and we look forward to working with 3P.”

The agreement

According to the agreement, 3P is responsible for transferring the process developed by Affibody to its facilities prior to execution of the first GMP manufacturing batches. 3P will also perform the process characterization and the process validation before entering the commercial batch manufacturing stage.

“We are very pleased to be working with Affibody on this project and to create a strong long-term partnership with them. We are sure that this is a mutually beneficial agreement,” says Dámaso Molero, General Manager at 3P Biopharmaceuticals.